Notice of Extraordinary General Meeting in Senzime AB (publ)

The shareholders in Senzime AB (publ) reg. no. 556565-5734 (the “Company”) are hereby convened to the extraordinary general meeting at 9.30 (local time) on Friday 3 March 2017 in the premises of Advokatfirman Lindahl at Vaksalagatan 10, 753 20, Uppsala.

is planning to carry out a fully underwritten rights issue for further market launches and is taking steps toward listing at Nasdaq First North

Uppsala February 16, 2017. The Board of Senzime AB (publ) proposes that an extra general meeting resolves on a rights issue of approximately SEK 24.4 million before issue costs. The rights issue is fully underwritten by the company's principal owner. The proceeds will be used to enable the commercialization of Senzimes products and strengthen its financial position. Concurrently Senzime is planning a listing at Nasdaq First North.

Senzime signs distribution agreements for the TetraGraph

Uppsala, February 9, 2017. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in the UK, Ireland, Australia and New Zealand.

Senzime reports initial evaluation from the clinical trial at NorthShore in Chicago, USA

Uppsala, January 23, 2017.  Senzime AB (publ) reports initial feedback from the clinical trials at NorthShore University HealthSystem, Chicago, USA, a Teaching Affiliate of the University of Chicago Pritzker School of Medicine. Professor Glenn Murphy is a world-leading clinical investigator and authority in postoperative complications that result from residual neuromuscular block in patients undergoing surgery and general anesthesia. He is the lead investigator of the study that examines the clinical utility of the TetraGraph System, and compares its ease of use, reliability and precision to the TOF-Watch, the former leading neuromuscular monitor that has been discontinued from the market.

Senzime announces the nomination committee for the AGM 2017

Uppsala, January 20, 2017. Senzime announces the nomination committee for the AGM 2017.

Senzime announces that yearend report 2016 to be released February 16, 2017

Uppsala, January 20, 2017. The Board of Senzime has decided that the yearend report is to be released one week earlier than announced.

Senzime reports completion of trial

Uppsala, January 12, 2017.  Senzime AB (publ) reports completion of the initial volunteer study performed at the Mayo Clinic in the USA. The study evaluated the ease of use, required set-up time, and volunteer comfort during testing using Senzime’s patient neuromonitoring system, the TetraGraph.

Senzime launches OnZurf Probe for preclinical use

Uppsala, December 19, 2016. Senzime launches OnZurf Probe for use in preclinical research. Onzurf Probe is a new generation of microdialysis probe (catheter) that allows organ-specific monitoring after surgery on organs such as the esophagus, bowel and liver. Onzurf Probe has a unique mode of attachment to the target organ, allowing easy placement of the microdialysis catheter on the surface of the organ. This non-invasive technique obviates the need for penetrating surgical instruments that can cause tissue trauma and stress during placement of the probe. 

Senzime signs license agreement with Fukuda Denshi

Uppsala, December 5, 2016. Senzime AB (publ) has signed an exclusive licensing agreement with Japanese Fukuda Denshi Co Ltd (“Fukuda”). The agreement gives Fukuda the exclusive right to license and commercialize Senzime’s TetraGraph system in Japan with market launch expected by the end of 2017. Senzime’s management and board expects this 10-year agreement to generate more than SEK 100 million in license revenue related to future milestone payments and royalties.

Senzime to conduct clinical trial at University of Debrecen, Hungary

Uppsala, November 15, 2016: Senzime (publ) launches a clinical study at the University of Debrecen, Hungary. This study will evaluate Senzime’s patient neuromonitoring system called TetraGraph, used during anesthesia. This study is designed to investigate the clinical utility of the system in a total of 40 patients, and will compare its ease of use, reliability and precision to the former leading product, the TOF-Watch, that has been discontinued from the market. Results are scheduled for presentation as early as the first quarter of 2017.

Senzime to conduct clinical trial at NorthShore in Chicago, USA

Uppsala, November 7, 2016: Senzime (publ) launches a clinical study at NorthShore University HealthSystem, Chicago, USA, a Teaching Affiliate of the University of Chicago Pritzker School of Medicine. Professor Glenn Murphy is a world-leading authority and clinical investigator of complications that result from residual neuromuscular block in patients undergoing surgery and general anesthesia.  Professor Murphy will head this clinical investigation of the leading neuromuscular monitoring system, the TetraGraph. This study is designed to investigate the clinical utility of the TetraGraph System in a total of 150 patients, and will compare its ease of use, reliability and precision to the former leading product that has been discontinued from the market.

Senzime to conduct studies at Mayo Clinic, US

Uppsala, November 1, 2016. Senzime (publ) is initiating a series of clinical studies to be performed at Mayo Clinic, USA. The studies are intended to evaluate Senzime’s patient neuromonitoring system called TetraGraph, used during anesthesia. Data about the monitor’s ease of clinical use, form factor, design, and ease of set-up will be collected. The clinical validation studies at Mayo Clinic are intended to compare its usability to that of the now-discontinued former market leading monitoring system. Results are scheduled for presentation as early as December 2016.

New Swedish registry study

Uppsala, 12 October 2016. New Swedish registry study – a national collaboration between Senzime, Swedish Medtech, Skåne University Hospital in Lund and University of Gothenburg and the national quality registry for esophageal and gastric cancer.  A clinical trial investigating the OnZurf Probe for continuous, organ specific monitoring of lactate trends in postoperative esophageal cancer patients is ongoing in Lund. Esophageal cancer is a worldwide disease that affects about 500 000 patients annually.  The clinical trial is being expanded in order to examine how the new OnZurf Probe solution may mitigate the healthcare costs associated with this disease. The results from the expanded study are expected to be published in the second quarter of 2017.

Summary of Interim Report January – June, 2016

“We’re building a new global leader in the field of patient monitoring”

Senzime in collaboration with Örebro University

Uppsala, August 25, 2016. Örebro University has been awarded SEK 11 million and will together with Senzime, Sandvik, Techtum and Nanoxis explore why the immune system reacts differently in different people after an operation, during an infection or because of polluted air.

The Board of Senzime has decided that the half-year financial report is postponed to August 31, 2016.

Outcome of Senzimes rights issue

Uppsala, June 21, 2016. The subscription period for Senzime AB's new share issue with preferential rights for existing shareholders expired on 15 June 2016. The final outcome shows that the share issue was subscribed to 92.6 percent of the original offer. The remaining 7.5 percent of the shares is allocated to the underwriters. The proceeds in the issue totals approximately SEK 15.3 million before transaction costs.

Senzime strengthens management - hires new CFO and Director of Business Development

Uppsala, June 7, 2016. Senzime AB (publ) has hired Jessica Roxhed as new CFO and Catrin Molund as new Director of Business development. Jessica joins with experience from various financial positions within Life Science and most recently the Church of Sweden, where she was controller. Catrin joins with a long term career in various management positions at Orexo AB, a publically traded specialty pharmaceutical company. Both will join from September 1.

Senzime acquires Acacia Designs and issues new shares in a guaranteed rights issue

Uppsala, May 3, 2016. Senzime AB (publ.) ("Senzime") has entered into an agreement to acquire Acacia Designs BV ("Acacia"), an international development company within anesthesia monitoring. The acquisition will be financed by 16,076,730 newly issued shares in Senzime through a non-cash issue. After the acquisition, Acacia’s shareholders will own 50 percent of the shares in Senzime. In connection with the acquisition, a rights offering to existing shareholders will be made, amounting to 15.2 million SEK before transaction expenses. The rights offering is fully guaranteed through subscription commitments and guarantees.

Senzime receives research grant from Bio-X

Uppsala, April 19, 2016. Senzime receives research grant from Vinnova through Bio-X, to conduct a study designed for clinical evaluation of OnZurf Probe and CliniSenz Analyzer for postoperative monitoring of patients with esophagus cancer. The grant also provides the ability to carry out activities prior to commercialization and CE marking of the products. The grant amounts to SEK 2 million, and the study will be conducted in Lund.

Senzime appointed to CEBR’s "hotlist"

Uppsala, March 18, 2016. Senzime has been appointed one of ten leading medical technology companies by the CEBR - Council for European bioregions. The appointment is a further proof of Senzime’s technologies within the important and large commercial area in measurement of glucose and lactate which is critical to quickly detect complications after operations and control for treatments.

Senzime expands the company's advisory board and appoints new CTO

Uppsala, 20 November 2015. Senzime today announced that the company's advisory board includes two new members with complementary experiences of entrepreneurship, diagnostics and surgery.  Furthermore, Anders Jacobson is appointed new CTO (Chief Technical Officer); his background is instrument development for which he was responsible at Biotage AB.

"OnZurf probe" nominated for the Athena Award 2015

Translation of press release published Monday November 2, 2015 Uppsala, November 2, 2015. Senzime’s (publ) OnZurf probe is nominated for Sweden's largest prize for outstanding achievements in clinical research. The Athena Award recognizes research done in collaboration between healthcare, academia and industry, and the research shall be of benefit to patients and healthcare.

Senzimes ”OnZurf probe” nominerad till Athenapriset 2015

Uppsala, 2 november, 2015. Senzimes (publ) OnZurf probe är nominerad till Sveriges största pris för framstående insatser inom klinisk forskning. Athenapriset belönar forskning som sker i samverkan mellan sjukvård, akademi och näringslivet och forskningen ska vara till nytta för patienter och sjukvård.

1|2|3|4|5